The Manchester Lung Health Study (qUEST) will assess the uptake of a community-based lung cancer screening service and its impact across a deprived area of North and East Manchester, which has high rates of lung cancer. One measure will be to compare the number and stage of lung cancers detected through screening to those detected outside of screening. In addition we will investigate the potential of a blood and nose test to detect lung cancer or to help decide who would benefit from screening. We will also see if these samples can help with the interpretation of CT scans. One of the problems with lung cancer CT screening is that you detect lung nodules in which we are not sure if they are benign or cancerous. Therefore we are also looking to see if a biomarker can help us work out which are cancerous and which are benign.
Study Type
OBSERVATIONAL
Enrollment
9,730
The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
Manchester University NHS Trust
Manchester, United Kingdom
RECRUITINGUptake of the Manchester lung health check service
The overall uptake will be assessed and analysed according to age, sex, smoking status, ethnicity and socio economic status.
Time frame: Over 3 years to determine long term outcomes from screening
Evaluation of biomarkers
Sensitivity and specificity of a biomarker or panel of biomarkers to detect early stage lung cancer.
Time frame: Over 3 years to determine long term outcomes from screening
Screening adherence
overall and according to patient characteristics (age, sex, smoking status, ethnicity and socio economic status).
Time frame: Over 3 years to determine long term outcomes from screening
Evaluation of screening numbers required to detect lung cancer
Number needed to screen to detect one lung cancer according to lung cancer risk (as calculated by PLCOM2012).
Time frame: Over 3 years to determine long term outcomes from screening
Comparison between cohort and those residents diagnosed in north and east manchester
Lung cancer stage in the screened cohort compared to lung cancers diagnosed in residents of N+EM outside of the screening service.
Time frame: Over 3 years to determine long term outcomes from screening
Histological subtype for lung cancer related to screening service
Histological subtype of lung cancers in screening and outside of screening during the course of the service.
Time frame: Over 3 years to determine long term outcomes from screening
Treatment for lung cancer related to screening service
Treatment of lung cancers in screening and outside of screening during the course of the service.
Time frame: Over 3 years to determine long term outcomes from screening
Diagnosis route for lung cancer related to screening service
Route to diagnosis of lung cancers in screening and outside of screening during the course of the service.
Time frame: Over 3 years to determine long term outcomes from screening
False positive rates
False positive rates in those undergoing LDCT screening.
Time frame: Over 3 years to determine long term outcomes from screening
False negative rates
False negative rates in those undergoing LDCT screening.
Time frame: Over 3 years to determine long term outcomes from screening
Rates of investigation of benign disease
Rates of investigation of benign disease in those undergoing LDCT screening.
Time frame: Over 3 years to determine long term outcomes from screening
Benign resection rate in participants
Benign resection rate in participants for those that have undergoing LDCT screening.
Time frame: Over 3 years to determine long term outcomes from screening
Interval cancers
Interval cancers in those undergoing LDCT screening.
Time frame: Over 3 years to determine long term outcomes from screening
Recall rates
Recall rates in those undergoing LDCT screening.
Time frame: Over 3 years to determine long term outcomes from screening
Resection rates generated from screening
Resection rates generated from screening including incidental findings.
Time frame: Over 3 years to determine long term outcomes from screening
Investigations generated from screening
Investigations generated from screening including incidental findings.
Time frame: Over 3 years to determine long term outcomes from screening
Adverse events generated from screening
Adverse events generated from screening including incidental findings.
Time frame: Over 3 years to determine long term outcomes from screening
Assessment of the British Thoracic Society pulmonary nodule guidelines
Assessment of performance of the BTS pulmonary nodules guideline in the setting of screening service.
Time frame: Over 3 years to determine long term outcomes from screening
Smoking prevalence
Smoking prevalence and amount at the start and end of screening.
Time frame: Over 3 years to determine long term outcomes from screening
Undiagnosed airflow obstruction
Prevalence of undiagnosed airflow obstruction in the screened population.
Time frame: Over 3 years to determine long term outcomes from screening
Coronary artery calcification
Prevalence of coronary artery calcification and QRISK2 score.
Time frame: Over 3 years to determine long term outcomes from screening
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.